StockData
Surrozen, Inc./DE logo

Surrozen, Inc./DE (SRZN) stock

SRZNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 5/30
$29.98−2.34 (-7.24%)

Close on Nov 17, 2026Market cap $352.37MP/E –Yield –

Surrozen r&d expenses

Research and development expenses are spending on new products and technology.

Surrozen's R&D Expenses for the twelve months ending Jun 30, 2026 was $34.58M, up 49.4% year over year. For fiscal 2025 it was $29.37M, up 39.0% from the year before. The highest annual figure on record is $40.18M in fiscal 2021.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$29.37M+39.0%
FY2024Dec 31, 2024$21.13M-22.4%
FY2023Dec 31, 2023$27.23M-26.4%
FY2022Dec 31, 2022$37.01M-7.9%
FY2021Dec 31, 2021$40.18M+56.4%
FY2020Dec 31, 2020$25.68M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$8.48M+40.4%
Q1 FY2026Mar 31, 2026$9.33M+42.2%
Q4 FY2025Dec 31, 2025$8.99M+68.1%
Q3 FY2025Sep 30, 2025$7.77M+49.5%
Q2 FY2025Jun 30, 2025$6.04M-0.9%
Q1 FY2025Mar 31, 2025$6.56M+7.3%
Q4 FY2024Dec 31, 2024$5.35M-22.9%
Q3 FY2024Sep 30, 2024$5.20M-35.7%
Q4 FY2023Dec 31, 2023$6.10M-35.4%
Q3 FY2023Sep 30, 2023$6.11M-29.1%
Q2 FY2023Jun 30, 2023$6.94M-27.6%
Q1 FY2023Mar 31, 2023$8.09M-13.7%
Q4 FY2022Dec 31, 2022$9.44M-13.4%
Q3 FY2022Sep 30, 2022$8.62M-17.2%
Q2 FY2022Jun 30, 2022$9.58M-6.7%
Q1 FY2022Mar 31, 2022$9.37M+9.0%
Q4 FY2021Dec 31, 2021$10.89M+25.9%
Q3 FY2021Sep 30, 2021$10.42M+49.7%
Q2 FY2021Jun 30, 2021$10.27M–
Q1 FY2021Mar 31, 2021$8.60M–
Q4 FY2020Dec 31, 2020$8.65M–
Q3 FY2020Sep 30, 2020$6.96M–

More Surrozen figures

See a number that looks wrong?